From Lab to Clinic
CNBC International supplies the clearest clinical marker: CASGEVY became the first FDA-approved CRISPR gene therapy, treating transfusion-dependent beta thalassemia and a second inherited blood disorder. Bloomberg Originals steps back to 1975, when the Asilomar Conference produced practical and ethical guidelines. Together the two reports show a field that moved from voluntary restraint to approved medicine while the underlying CRISPR technique remained the same.






